Report: Keytruda and Opdivo to lead the immuno-oncology market
A GlobalData report estimates that two drugs, Keytruda and Opdivo, are estimated to account for 50% of the global immuno-oncology…
A GlobalData report estimates that two drugs, Keytruda and Opdivo, are estimated to account for 50% of the global immuno-oncology…